Screener
Arcutis Biotherapeutics, Inc. ARQT Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:07 PM EST
- Fiscal year
- FY2025
- Accession
- 0001787306-26-000018
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Net cash provided by (used in) investing activities | (30,253) | 28,820 | 180,232 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Proceeds from issuance of common stock, net of issuance costs | — | 161,682 | — |
| Repayment of long-term debt | — | (100,000) | — |
| Proceeds from issuance of common stock upon exercise of stock options | 4,597 | 2,807 | 1,247 |
| Proceeds from issuance of common stock for ESPP | 2,376 | 1,713 | 1,175 |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | — | — | 95,765 |
| Proceeds from issuance of shares under ATM, net of issuance costs | — | — | 3,136 |
Item 16. tem 16.
FAQ
- What is Arcutis Biotherapeutics, Inc.'s debt repayments?
- Arcutis Biotherapeutics, Inc. (ARQT) reported debt repayments of $0 in Q4 2025.
- How has Arcutis Biotherapeutics, Inc.'s debt repayments changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s debt repayments decreased by 100.0% year-over-year, from $25M to $0.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Arcutis Biotherapeutics, Inc.'s debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude